Korro Bio, Inc. Share-based Payment Arrangement, Noncash Expense
Korro Bio, Inc. (KRRO) reported Share-based Payment Arrangement, Noncash Expense of $9.25 million for the 9-month period ending 2023-09-30, per its 10-Q filed 2023-11-02.
Discontinued › Cash Flow › Operating Activities
us-gaap:ShareBasedCompensation · last filed 2023-11-02
- Korro Bio, Inc. share-based payment arrangement, noncash expense for the quarter ending 2023-09-30 was $2.92M, a 47.72% decline year-over-year.
- Korro Bio, Inc. share-based payment arrangement, noncash expense for the quarter ending 2023-06-30 was $2.90M, a 36.52% decline year-over-year.
- Korro Bio, Inc. share-based payment arrangement, noncash expense for the quarter ending 2023-03-31 was $3.43M, a 34.85% decline year-over-year.
- Korro Bio, Inc. share-based payment arrangement, noncash expense for the quarter ending 2022-12-31 was $4.41M, a 14.68% decline year-over-year.
- Korro Bio, Inc. share-based payment arrangement, noncash expense for fiscal 2022 was $19.83M, a 8.82% decline from fiscal 2021.
- Korro Bio, Inc. share-based payment arrangement, noncash expense for fiscal 2021 was $21.75M, a 117.87% increase from fiscal 2020.
- Korro Bio, Inc. share-based payment arrangement, noncash expense for fiscal 2020 was $9.98M, a 176.61% increase from fiscal 2019.
- Korro Bio, Inc. share-based payment arrangement, noncash expense for fiscal 2019 was $3.61M, a 693.19% increase from fiscal 2018.
| Period end | Share-based Payment Arrangement, Noncash Expense 3 month | Share-based Payment Arrangement, Noncash Expense 6 month | Share-based Payment Arrangement, Noncash Expense 9 month | Share-based Payment Arrangement, Noncash Expense 12 month |
|---|---|---|---|---|
| 2023-09-30 | $2.92M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-02 | $5.82M derived: sum of 2 quarters · filed 2023-11-02 | $9.25M 10-Q · filed 2023-11-02 | $13.66M derived: sum of 4 quarters · filed 2023-11-02 |
| 2023-06-30 | $2.90M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-10 | $6.33M 10-Q · filed 2023-08-10 | $10.73M derived: sum of 3 quarters · filed 2023-08-10 | $16.33M derived: sum of 4 quarters · filed 2023-11-02 |
| 2023-03-31 | $3.43M 10-Q · filed 2023-05-12 | $7.84M derived: sum of 2 quarters · filed 2023-05-12 | $13.43M derived: sum of 3 quarters · filed 2023-11-02 | $18.00M derived: sum of 4 quarters · filed 2023-11-02 |
| 2022-12-31 | $4.41M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-10 | $10.00M derived: sum of 2 quarters · filed 2023-11-02 | $14.56M derived: sum of 3 quarters · filed 2023-11-02 | $19.83M 10-K · filed 2023-03-10 |
| 2022-09-30 | $5.59M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-02 | $10.16M derived: sum of 2 quarters · filed 2023-11-02 | $15.43M 10-Q · filed 2023-11-02 | $20.59M derived: sum of 4 quarters · filed 2023-11-02 |
| 2022-06-30 | $4.56M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-10 | $9.83M 10-Q · filed 2023-08-10 | $14.99M derived: sum of 3 quarters · filed 2023-08-10 | $20.88M derived: sum of 4 quarters · filed 2023-08-10 |
| 2022-03-31 | $5.27M 10-Q · filed 2023-05-12 | $10.43M derived: sum of 2 quarters · filed 2023-05-12 | $16.32M derived: sum of 3 quarters · filed 2023-05-12 | $22.41M derived: sum of 4 quarters · filed 2023-05-12 |
| 2021-12-31 | $5.16M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-10 | $11.05M derived: sum of 2 quarters · filed 2023-03-10 | $17.14M derived: sum of 3 quarters · filed 2023-03-10 | $21.75M 10-K · filed 2023-03-10 |
| 2021-09-30 | $5.89M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-08 | $11.97M derived: sum of 2 quarters · filed 2022-11-08 | $16.59M 10-Q · filed 2022-11-08 | $19.35M derived: sum of 4 quarters · filed 2022-11-08 |
| 2021-06-30 | $6.09M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-09 | $10.70M 10-Q · filed 2022-08-09 | $13.46M derived: sum of 3 quarters · filed 2022-08-09 | $16.11M derived: sum of 4 quarters · filed 2022-08-09 |
| 2021-03-31 | $4.61M 10-Q · filed 2022-05-04 | $7.38M derived: sum of 2 quarters · filed 2022-05-04 | $10.02M derived: sum of 3 quarters · filed 2022-05-04 | $12.43M derived: sum of 4 quarters · filed 2022-05-04 |
| 2020-12-31 | $2.77M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-15 | $5.41M derived: sum of 2 quarters · filed 2022-03-15 | $7.82M derived: sum of 3 quarters · filed 2022-03-15 | $9.98M 10-K · filed 2022-03-15 |
| 2020-09-30 | $2.64M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-15 | $5.05M derived: sum of 2 quarters · filed 2021-11-15 | $7.22M 10-Q · filed 2021-11-15 | $8.37M derived: sum of 4 quarters · filed 2021-11-15 |
| 2020-06-30 | $2.41M derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-12 | $4.58M 10-Q · filed 2021-08-12 | $5.73M derived: sum of 3 quarters · filed 2021-08-12 | $6.65M derived: sum of 4 quarters · filed 2021-08-12 |
| 2020-03-31 | $2.16M 10-Q · filed 2021-05-13 | $3.32M derived: sum of 2 quarters · filed 2021-05-13 | $4.24M derived: sum of 3 quarters · filed 2021-05-13 | $5.72M derived: sum of 4 quarters · filed 2021-05-13 |
| 2019-12-31 | $1.15M derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-29 | $2.08M derived: sum of 2 quarters · filed 2021-03-29 | $3.56M derived: sum of 3 quarters · filed 2021-03-29 | $3.61M 10-K · filed 2021-03-29 |
| 2019-09-30 | $925.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-16 | $2.41M derived: sum of 2 quarters · filed 2020-11-16 | $2.46M 10-Q · filed 2020-11-16 | $2.64M derived: sum of 4 quarters · filed 2020-11-16 |
| 2019-06-30 | $1.48M derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-12 | $1.53M 10-Q · filed 2020-08-12 | $1.72M derived: sum of 3 quarters · filed 2020-08-12 | |
| 2019-03-31 | $49.00K 10-Q · filed 2020-05-14 | $237.00K derived: sum of 2 quarters · filed 2020-05-14 | ||
| 2018-12-31 | $188.00K derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-26 | $455.00K 10-K · filed 2020-03-26 | ||
| 2018-09-30 | $267.00K 10-Q · filed 2019-11-18 | |||
| 2017-12-31 | $91.00K 10-K · filed 2020-03-26 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Atrium Therapeutics, Inc. (RNA) | United States | $0.140B | |
| SPRUCE BIOSCIENCES, INC. (SPRB) | United States | $0.142B | -2.89 |
| Curanex Pharmaceuticals Inc (CURX) | United States | $0.138B | |
| Corbus Pharmaceuticals Holdings, Inc. (CRBP) | United States | $0.144B | -1.72 |
| Annexon, Inc. (ANNX) | United States | $0.147B | -4.22 |
| TuHURA Biosciences, Inc./NV (HURA) | United States | $0.134B | -4.88 |
| Unicycive Therapeutics, Inc. (UNCY) | United States | $0.134B | -3.70 |
| NRX Pharmaceuticals, Inc. (NRXP) | United States | $0.131B | -6.31 |
| MEDICINOVA INC (MNOV) | United States | $0.130B | -6.04 |
| IMMUNIC, INC. (IMUX) | United States | $0.127B | -1.88 |